We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+1.17%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.63B
AUM Growth
-$171M
Cap. Flow
-$213M
Cap. Flow %
-13.08%
Top 10 Hldgs %
50.48%
Holding
102
New
12
Increased
17
Reduced
20
Closed
14

Top Buys

Rank Stock Value
1
BHC icon
Bausch Health
BHC
+$101M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$28.5M
3
NVDQ
Novadaq Technologies Inc.
NVDQ
+$21.2M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$14.3M
5
PETX
Aratana Therapeutics, Inc.
PETX
+$14M

Top Sells

Rank Stock Value
1
EBS icon
Emergent Biosolutions
EBS
+$33.1M
2
NVRO
NEVRO CORP.
NVRO
+$21.7M
3
CSII
Cardiovascular Systems, Inc.
CSII
+$19M
4
MASI
Masimo
MASI
+$16.3M
5
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$15.1M

Sector Composition

Rank Sector Weight
1 Healthcare 78.51%
2 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
26
DELISTED
Zogenix, Inc.
ZGNX
$16M 0.99%
1,087,112
-20,093
-2% -$270K
DVAX
27
DELISTED
Dynavax Technologies
DVAX
$15.2M 0.94%
629,710
-160,000
-20% -$4.01M
CORI
28
DELISTED
Corium International, Inc.
CORI
$14.6M 0.9%
1,802,092
– –
AMPH icon
29
Amphastar Pharmaceuticals
AMPH
$825M
$14.6M 0.9%
1,026,979
-250,000
-20% -$3.3M
ZVRA icon
30
Zevra Therapeutics
ZVRA
$563M
$14.5M 0.89%
45,771
-4,216
-8% -$1.14M
ATRS
31
DELISTED
Antares Pharma, Inc.
ATRS
$13.9M 0.85%
11,475,000
+3,000,000
+35% +$4.18M
ASRT
32
DELISTED
Assertio
ASRT
$13.2M 0.81%
+12,093
New +$13.6M
RPTP
33
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$12.5M 0.77%
2,412,995
+1,000,000
+71% +$5.8M
EGLT
34
DELISTED
Egalet Corporation
EGLT
$12.5M 0.77%
1,134,750
– –
STJ
35
DELISTED
St Jude Medical
STJ
$12.4M 0.76%
+200,000
New +$12.6M
QLTI
36
DELISTED
QLT Inc
QLTI
$11.8M 0.73%
4,445,527
– –
DSCI
37
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$11.7M 0.72%
2,562,104
+200,000
+8% +$948K
SBBP
38
DELISTED
Strongbridge Biopharma plc.
SBBP
$10.9M 0.67%
+1,656,705
New +$11.9M
HZNP
39
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$10.8M 0.67%
500,000
– –
RDHL
40
Redhill Biopharma
RDHL
$3.85M
$10.7M 0.66%
830
– –
TRVN
41
DELISTED
Trevena, Inc.
TRVN
$10.5M 0.65%
1,600
-125
-7% -$838K
CPRX
42
DELISTED
Catalyst Pharmaceutical
CPRX
$10.2M 0.63%
4,183,177
– –
BHC icon
43
CALL
Bausch Health
BHC
$1.65B
$10.2M 0.63%
+100,000
New +$11.2M
PRTK
44
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$10.1M 0.62%
530,283
– –
ELGX
45
DELISTED
Endologix Inc
ELGX
$9.9M 0.61%
+100,000
New +$10.7M
ARCT icon
46
Arcturus Therapeutics
ARCT
$157M
$9.78M 0.6%
222,444
– –
ACGN
47
DELISTED
Aceragen Inc
ACGN
$9.56M 0.59%
22,778
-15,598
-41% -$6.98M
RIGL icon
48
Rigel Pharmaceuticals
RIGL
$680M
$9.47M 0.58%
312,528
-200,000
-39% -$6.06M
AMAG
49
DELISTED
AMAG Pharmaceuticals
AMAG
$9.06M 0.56%
+300,000
New +$9.69M
CYNA
50
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$8.92M 0.55%
583,121
-2,996
-0.5% -$45.5K
1
2
3 4 5

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q4 2015 Portfolio in Review

As of Q4 2015, Broadfin Capital held 102 positions worth $1.63B, down 9.5% from $1.8B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Broadfin Capital withdrew a net $213M in Q4 2015, closing 14 positions and reducing 20 holdings. Its most notable exit was Cardiovascular Systems, Inc., an estimated $19M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 63% a quarter earlier, followed by Technology.

Against the trend, Broadfin Capital opened a new position in Bausch Health worth $91.5M.

  • Broadfin Capital's largest Q4 2015 buy was Bausch Health: 900,000 shares worth $91.5M.
  • Broadfin Capital added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015, an estimated $28.5M increase.
  • Broadfin Capital's biggest Q4 2015 reduction was Emergent Biosolutions, cutting an estimated $33.1M.
  • Broadfin Capital fully exited Cardiovascular Systems, Inc. in Q4 2015, selling an estimated $19M.
  • Broadfin Capital's ten largest holdings make up 50% of its $1.63B portfolio in Q4 2015.
  • Broadfin Capital opened 12 new positions and closed 14 in Q4 2015.
  • Broadfin Capital's portfolio value fell 9.5% quarter-over-quarter to $1.63B.

Based on Broadfin Capital's 13F filing for Q4 2015, filed 16 Feb 2016.